Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

10.6K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
10.6K
Abnormal Proliferation02:23

Abnormal Proliferation

4.9K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

4.8K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.2K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.2K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

5.4K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.4K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

17.3K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
17.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ETL Pipelines for Nationwide Oncology Data Integration in DNPM.

Studies in health technology and informatics·2026
Same author

Sphingosine-1-Phosphate-derived 2-Hexadecenal is a central mediator of ocular neovascularization by inhibiting Sphingosine-1-Phosphate receptor 5.

Nature communications·2026
Same author

Implementing whole genome and transcriptome sequencing for cancer patients in routine healthcare: a comprehensive guide to costing.

British journal of cancer·2026
Same author

Defining Histological Patterns in Inherited Ichthyoses: Toward a Diagnostic Algorithm Based on 66 Confirmed Cases.

Dermatopathology (Basel, Switzerland)·2026
Same author

Strawberry Notch 1 Acts as a Transcriptional Regulator Driving Oncogenic Programs in Liver Carcinogenesis.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Activated ATF6α is a hepatic tumour driver restricting immunosurveillance.

Nature·2026

Related Experiment Video

Updated: Nov 28, 2025

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.4K

Prohibitin, STAT3 and SH2D4A physically and functionally interact in tumor cell mitochondria.

Carolin Ploeger1, Thorben Huth1, Raisatun Nisa Sugiyanto1

  • 1Department of General Pathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.

Cell Death & Disease
|December 1, 2020
PubMed
Summary

The tumor suppressor SH2D4A interacts with STAT3 in mitochondria, impacting cancer cell respiration. Inhibiting this interaction with FL3 may offer new cancer therapies by reducing STAT3 activity and mitochondrial function.

More Related Videos

Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer
04:20

Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer

Published on: February 9, 2024

1.2K
Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes
09:40

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes

Published on: September 28, 2018

15.5K

Related Experiment Videos

Last Updated: Nov 28, 2025

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.4K
Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer
04:20

Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer

Published on: February 9, 2024

1.2K
Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes
09:40

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes

Published on: September 28, 2018

15.5K

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Chromosome 8p deletions are common in cancers and linked to poor survival.
  • SH2D4A, located on 8p, inhibits the pro-tumorigenic transcription factor STAT3 nuclear translocation.
  • Investigating non-canonical STAT3 functions with tumor suppressor SH2D4A is crucial.

Purpose of the Study:

  • To explore the interaction between SH2D4A and STAT3.
  • To elucidate the role of SH2D4A in STAT3's non-canonical functions.
  • To identify potential therapeutic targets involving SH2D4A and STAT3.

Main Methods:

  • Immunoprecipitation-mass spectrometry (IP-MS) to identify binding partners.
  • Co-immunoprecipitation and proximity ligation assays for interaction validation.
  • Cell fractionation, immunofluorescence, and pharmacological inhibition (FL3) to study protein localization and function.

Main Results:

  • SH2D4A interacts with mitochondrial scaffold proteins prohibitin 1 (PHB1) and prohibitin 2 (PHB2).
  • STAT3, PHB1, and SH2D4A co-localize in mitochondria and interact directly.
  • FL3 treatment disrupts these interactions, reduces STAT3 activity, and impairs mitochondrial respiration.

Conclusions:

  • SH2D4A and PHB1 interaction is vital for mitochondrial function and integrity.
  • SH2D4A links STAT3 to mitochondrial functions, reducing its transcriptional activity.
  • Inhibiting PHB interactions with FL3 shows therapeutic potential against STAT3-activated tumors.